Physician profile
John R Todd
NPI 1730101205
$3,550.89
in general payments reported to CMS, 2019-2025
18 companies · $625 in 2025
The $625 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $688 · 2020: $180 · 2021: $166 · 2022: $711 · 2023: $650 · 2024: $531 · 2025: $625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,807.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,806.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,023.05 | 2019-2025 | Avycaz, Dalvance |
| Merck Sharp & Dohme LLC | $635.42 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Insmed, INC. | $381.78 | 2019-2024 | Arikayce |
| Paratek Pharmaceuticals, INC. | $322.50 | 2021-2025 | Nuzyra |
| Shionogi INC | $219.04 | 2022-2025 | Fetroja |
| Astellas Pharma US INC | $216.96 | 2022-2025 | Cresemba |
| Viiv Healthcare Company | $175.01 | 2019-2023 | Dovato |
| Melinta Therapeutics, LLC | $131.74 | 2019-2025 | Kimyrsa, Rezzayo, Orbactiv |
| Tetraphase Pharmaceuticals, INC. | $125.00 | 2019 | |
| Allergan, INC. | $89.09 | 2019 | |
| Gilead Sciences, INC. | $66.07 | 2019-2024 | Sunlenca, Veklury |
| Theratechnologies INC. | $38.27 | 2025 | Trogarzo, Egrifta |
| La Jolla Pharmaceutical Company | $37.16 | 2024-2025 | Xacduro |
| Emd Serono, INC. | $24.66 | 2025 | |
| Ferring Pharmaceuticals INC. | $18.45 | 2023 | Rebyota |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Invivyd INC | $18.30 | 2025 | Pemgarda |
| Aimmune Therapeutics, INC. | $17.25 | 2024 | |
| Janssen Biotech, INC. | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Todd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.